Why Immunogenicity in Drug Development Matters Immunogenicity, why do we keep talking about it? Immunogenicity can, in the simplest of terms, be described as a subject’s ability to generate antibodies specific to the dosed protein therapeutic. Immunogenicity can be either a wanted or unwanted reaction. Wanted immunogenicity is the desired…

If you’ve worked in drug development, you already know that the road from discovery to clinical success is long, expensive, and rarely linear. One of the most pivotal checkpoints in that journey is cytotoxicity testing. Whether you’re developing a small molecule, a biologic, or a cell therapy like CAR‑T, the…

Locked Nucleic Acids (LNAs) are RNA analogs that provide more stable Watson-Crick base-pairing. LNA ribonucleotides can be added into RNA and DNA oligonucleotides to increase the affinity of these oligonucleotides for their complementary sequences. In addition, these LNA present oligonucleotides have extraordinary single-nucleotide discrimination as well as enhanced stability, as…

Screening experiments have become the backbone of modern drug discovery and biological research, enabling the evaluation of thousands of compounds simultaneously. However, screening success hinges on two critical factors: (1) selecting appropriate cellular models and (2) designing robust experimental frameworks. Poor choices can lead to irreproducible results, failed clinical translation,…

In biomarker-driven drug development, selecting the right assay format is critical for generating reliable data that informs scientific and clinical decisions. Whether quantifying proteins, immune cell subsets, or complex molecular signatures, the choice between off-the-shelf and customized assays has direct implications for timelines, costs, and how well the assay performance…